secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001104659-22-123467
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte appoints Patrick Balthrop as non-executive director; grants 100,000 stock options
--------------------------------------------------------------------------------

- Patrick Balthrop appointed as Class II director and member of Nominating and Corporate Governance Committee effective Nov 30, 2022.
- Granted 100,000 nonqualified stock options at $5.99/share, vesting over three years with 1/3 after 12 months.
- Balthrop has 35+ years in life sciences; former CEO of Luminex, President of Fisher Healthcare, Abbott Laboratories veteran.
- No related party transactions or family relationships with existing directors or officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465922123467/0001104659-22-123467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465922123467/tm2231548d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-123467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer